{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:45:32Z","timestamp":1783471532957,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81802561"],"award-info":[{"award-number":["81802561"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hunan Province, China","doi-asserted-by":"crossref","award":["2023JJ30881"],"award-info":[{"award-number":["2023JJ30881"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biol Eng"],"DOI":"10.1186\/s13036-025-00535-7","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T16:30:23Z","timestamp":1752251423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Enhancing the therapeutic efficacy of gemcitabine in bladder cancer through TGF-\u03b21 inhibition and pluronic F-127-based microsphere delivery"],"prefix":"10.1186","volume":"19","author":[{"given":"Yaoyao","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangle","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"535_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"535_CR2","doi-asserted-by":"publisher","first-page":"1170124","DOI":"10.3389\/fonc.2023.1170124","volume":"13","author":"K Grabe-Heyne","year":"2023","unstructured":"Grabe-Heyne K, et al. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023;13:1170124. https:\/\/doi.org\/10.3389\/fonc.2023.1170124.","journal-title":"Front Oncol"},{"key":"535_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1756287211431976","volume":"4","author":"A Anastasiadis","year":"2012","unstructured":"Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol. 2012;4:13\u201332. https:\/\/doi.org\/10.1177\/1756287211431976.","journal-title":"Ther Adv Urol"},{"key":"535_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234\u201341. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033.","journal-title":"Eur Urol"},{"key":"535_CR5","first-page":"314","volume":"7","author":"TS Lawrence","year":"2001","unstructured":"Lawrence TS, Davis MA, Hough A, Rehemtulla A. The role of apoptosis in 2\u2019,2\u2019-difluoro-2\u2019-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res. 2001;7:314\u20139.","journal-title":"Clin Cancer Res"},{"key":"535_CR6","doi-asserted-by":"publisher","unstructured":"Han M et al. A 2021 Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev 6 CD009294 https:\/\/doi.org\/10.1002\/14651858.CD009294.pub3.","DOI":"10.1002\/14651858.CD009294.pub3"},{"key":"535_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1586\/14737140.2016.1143777","volume":"16","author":"K Schlack","year":"2016","unstructured":"Schlack K, Boegemann M, Steinestel J, Schrader AJ, Krabbe LM. The safety and efficacy of gemcitabine for the treatment of bladder cancer. Expert Rev Anticancer Ther. 2016;16:255\u201371. https:\/\/doi.org\/10.1586\/14737140.2016.1143777.","journal-title":"Expert Rev Anticancer Ther"},{"key":"535_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.urology.2021.04.062","volume":"156","author":"JM Kuperus","year":"2021","unstructured":"Kuperus JM, et al. Comparison of side effects and tolerability between intravesical Bacillus Calmette-Guerin, Reduced-Dose BCG and gemcitabine for Non-Muscle invasive bladder Cancer. Urology. 2021;156:191\u20138. https:\/\/doi.org\/10.1016\/j.urology.2021.04.062.","journal-title":"Urology"},{"key":"535_CR9","doi-asserted-by":"publisher","unstructured":"Moustakas A, Heldin CH. Mechanisms of TGFbeta-Induced Epithelial-Mesenchymal transition. J Clin Med. 2016;5. https:\/\/doi.org\/10.3390\/jcm5070063.","DOI":"10.3390\/jcm5070063"},{"key":"535_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12885-017-3537-5","volume":"17","author":"L Sommerova","year":"2017","unstructured":"Sommerova L, Ondrouskova E, Vojtesek B, Hrstka R. Suppression of AGR2 in a TGF-beta-induced Smad regulatory pathway mediates epithelial-mesenchymal transition. BMC Cancer. 2017;17:546. https:\/\/doi.org\/10.1186\/s12885-017-3537-5.","journal-title":"BMC Cancer"},{"key":"535_CR11","doi-asserted-by":"publisher","first-page":"100773","DOI":"10.1016\/j.tranon.2020.100773","volume":"13","author":"D Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T. Epithelial-Mesenchymal transition in cancer: A historical overview. Transl Oncol. 2020;13:100773. https:\/\/doi.org\/10.1016\/j.tranon.2020.100773.","journal-title":"Transl Oncol"},{"key":"535_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2021","unstructured":"Derynck R, Turley SJ, Akhurst RJ. TGFbeta biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021;18:9\u201334. https:\/\/doi.org\/10.1038\/s41571-020-0403-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"535_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40779-024-00550-7","volume":"11","author":"Y Zhuo","year":"2024","unstructured":"Zhuo Y, et al. TGF-\u03b21 mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neural functional recovery in parkinson\u2019s disease models and patients. Military Med Res. 2024;11:48. https:\/\/doi.org\/10.1186\/s40779-024-00550-7.","journal-title":"Military Med Res"},{"key":"535_CR14","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741\u201351. https:\/\/doi.org\/10.1038\/onc.2010.215.","journal-title":"Oncogene"},{"key":"535_CR15","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1038\/s41388-018-0378-x","volume":"37","author":"J van Staalduinen","year":"2018","unstructured":"van Staalduinen J, Baker D, Ten Dijke P, van Dam H. Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene. 2018;37:6195\u2013211. https:\/\/doi.org\/10.1038\/s41388-018-0378-x.","journal-title":"Oncogene"},{"key":"535_CR16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature15748","volume":"527","author":"KR Fischer","year":"2015","unstructured":"Fischer KR, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527:472\u20136. https:\/\/doi.org\/10.1038\/nature15748.","journal-title":"Nature"},{"key":"535_CR17","doi-asserted-by":"publisher","unstructured":"Li L, Wang S, Zhou W. Balance Cell Apoptosis and Pyroptosis of Caspase-3-Activating Chemotherapy for Better Antitumor Therapy. Cancers 15. https:\/\/doi.org\/10.3390\/cancers15010026 (2022).","DOI":"10.3390\/cancers15010026"},{"key":"535_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s0378-5173(01)00748-7","volume":"224","author":"M Burjak","year":"2001","unstructured":"Burjak M, Bogataj M, Velnar M, Grabnar I, Mrhar A. The study of drug release from microspheres adhered on pig vesical mucosa. Int J Pharm. 2001;224:123\u201330. https:\/\/doi.org\/10.1016\/s0378-5173(01)00748-7.","journal-title":"Int J Pharm"},{"key":"535_CR19","doi-asserted-by":"publisher","first-page":"6493","DOI":"10.2147\/IJN.S93750","volume":"10","author":"ZA Senyigit","year":"2015","unstructured":"Senyigit ZA, et al. Design and evaluation of an intravesical delivery system for superficial bladder cancer: Preparation of gemcitabine HCl-loaded chitosan-thioglycolic acid nanoparticles and comparison of chitosan\/poloxamer gels as carriers. Int J Nanomed. 2015;10:6493\u2013507. https:\/\/doi.org\/10.2147\/IJN.S93750.","journal-title":"Int J Nanomed"},{"key":"535_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s0168-3659(01)00488-6","volume":"78","author":"JL Au","year":"2002","unstructured":"Au JL, Jang SH, Wientjes MG. Clinical aspects of drug delivery to tumors. J Control Release. 2002;78:81\u201395. https:\/\/doi.org\/10.1016\/s0168-3659(01)00488-6.","journal-title":"J Control Release"},{"key":"535_CR21","doi-asserted-by":"publisher","unstructured":"Hombach J, Bernkop-Schnurch A. Mucoadhesive drug delivery systems. Handb Exp Pharmacol. 2010;251\u201366. https:\/\/doi.org\/10.1007\/978-3-642-00477-3_9.","DOI":"10.1007\/978-3-642-00477-3_9"},{"key":"535_CR22","doi-asserted-by":"crossref","unstructured":"Joshi P, Choudhary R, Kohli P, Pahariya P, Vargas-Lizarazo AY. Monitoring storage characteristics of gray mold inoculated strawberries treated with limonene liposome and oxygen absorbers and prediction of sensory shelf\u2010life with UV\u2010VIS\u2010NIR reflectance. eFood 5, e174 (2024).","DOI":"10.1002\/efd2.174"},{"key":"535_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/02652049209021220","volume":"9","author":"F Forni","year":"1992","unstructured":"Forni F, Vandelli MA, Cameroni R. Influence of drug loading level on drug release and dynamic swelling of crosslinked gelatin microspheres. J Microencapsul. 1992;9:29\u201339. https:\/\/doi.org\/10.3109\/02652049209021220.","journal-title":"J Microencapsul"},{"key":"535_CR24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1097\/01.ju.0000168657.51551.49","volume":"174","author":"CP Brocks","year":"2005","unstructured":"Brocks CP, B\u00fcttner H, B\u00f6hle A. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. J Urol. 2005;174:1115\u20138. https:\/\/doi.org\/10.1097\/01.ju.0000168657.51551.49.","journal-title":"J Urol"},{"key":"535_CR25","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.2147\/CMAR.S208984","volume":"11","author":"J Zou","year":"2019","unstructured":"Zou J, et al. Secreted TGF-beta-induced protein promotes aggressive progression in bladder cancer cells. Cancer Manag Res. 2019;11:6995\u20137006. https:\/\/doi.org\/10.2147\/CMAR.S208984.","journal-title":"Cancer Manag Res"},{"key":"535_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.urolonc.2011.02.003","volume":"31","author":"O Shaker","year":"2013","unstructured":"Shaker O, Hammam O, Wishahi M, Roshdi M. TGF-B1 pathway as biological marker of bladder carcinoma schistosomal and non-schistosomal. Urol Oncol. 2013;31:372\u20138. https:\/\/doi.org\/10.1016\/j.urolonc.2011.02.003.","journal-title":"Urol Oncol"},{"key":"535_CR27","doi-asserted-by":"publisher","unstructured":"Chrabanska M, Rynkiewicz M, Kiczmer P, Drozdzowska B. Immunohistochemical expression of CD44, MMP-2, MMP-9, and Ki-67 as the prognostic markers in Non-Clear cell renal cell Carcinomas-A prospective cohort study. J Clin Med. 2022;11. https:\/\/doi.org\/10.3390\/jcm11175196.","DOI":"10.3390\/jcm11175196"},{"key":"535_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.prp.2012.11.002","volume":"209","author":"N Mohtasham","year":"2013","unstructured":"Mohtasham N, et al. Immunohistochemical study of p53, Ki-67, MMP-2 and MMP-9 expression at invasive front of squamous cell and verrucous carcinoma in oral cavity. Pathol Res Pract. 2013;209:110\u20134.","journal-title":"Pathol Res Pract"},{"key":"535_CR29","doi-asserted-by":"publisher","first-page":"7809","DOI":"10.2147\/OTT.S212596","volume":"12","author":"HQ Zhou","year":"2019","unstructured":"Zhou HQ, et al. The TGF-beta\/Smad pathway inhibitor SB431542 enhances the antitumor effect of radiofrequency ablation on bladder Cancer cells. Onco Targets Ther. 2019;12:7809\u201321. https:\/\/doi.org\/10.2147\/OTT.S212596.","journal-title":"Onco Targets Ther"},{"key":"535_CR30","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1002\/fft2.466","volume":"5","author":"T Azevedo","year":"2024","unstructured":"Azevedo T, et al. Natural products-based antiangiogenic agents: new frontiers in cancer therapy. Food Front. 2024;5:2423\u201366.","journal-title":"Food Front"},{"key":"535_CR31","doi-asserted-by":"publisher","unstructured":"Hao Y, Baker D. Ten dijke, P. TGF-beta-Mediated Epithelial-Mesenchymal transition and Cancer metastasis. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20112767.","DOI":"10.3390\/ijms20112767"},{"key":"535_CR32","doi-asserted-by":"publisher","unstructured":"Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26. https:\/\/doi.org\/10.3390\/molecules26195905.","DOI":"10.3390\/molecules26195905"},{"key":"535_CR33","doi-asserted-by":"publisher","unstructured":"Helal-Neto E, et al. Molecular and cellular risk assessment of healthy human cells and Cancer human cells exposed to nanoparticles. Int J Mol Sci. 2019;21. https:\/\/doi.org\/10.3390\/ijms21010230.","DOI":"10.3390\/ijms21010230"},{"key":"535_CR34","doi-asserted-by":"publisher","unstructured":"Bai X, Smith ZL, Wang Y, Butterworth S, Tirella A. Sustained drug release from smart nanoparticles in Cancer therapy: A comprehensive review. Micromachines (Basel). 2022;13. https:\/\/doi.org\/10.3390\/mi13101623.","DOI":"10.3390\/mi13101623"}],"container-title":["Journal of Biological Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13036-025-00535-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13036-025-00535-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13036-025-00535-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:53:17Z","timestamp":1757224397000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbioleng.biomedcentral.com\/articles\/10.1186\/s13036-025-00535-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1186\/s13036-025-00535-7","relation":{},"ISSN":["1754-1611"],"issn-type":[{"value":"1754-1611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were conducted in accordance with institutional guidelines of experimental animals. This study has been carried out under the approval of the Medical Ethics Committee of Xiangya Hospital, Central South University. All participants in the study were informed and agreed to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}